|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Central Nervous System Neoplasms | |||||
| Glioblastoma | |||||
| Nervous System Neoplasms | |||||
| 2 | More general conditions related to this trial | ||||
| Astrocytoma | |||||
| Glioma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Nerve Tissue | |||||
| Neoplasms, Neuroepithelial | |||||
| Nervous System Diseases | |||||
| Neuroectodermal Tumors | |||||
| 3 | Interventions listed in this trial | ||||
| erlotinib hydrochloride | |||||
| temozolomide | |||||
| radiation therapy | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Erlotinib | |||||
| 5 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| North Central Cancer Treatment Group | |||||
| National Cancer Institute (NCI) | |||||